Search Results

Shockwave Medical, Inc. today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).

Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy to treat severely calcified cardiovascular disease, announced the completion of its previously announced acquisition of Neovasc Inc..

Neovasc, Inc. announced the German Institute for the Hospital Remuneration System has awarded the Neovasc Reducer™, a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) announced today that the Company has entered into a binding agreement (the “Arrangement Agreement”) with Shockwave Medical, Inc. (“Shockwave”), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the “Common Shares”) of the Company (the “Transaction”).

Neovasc Inc. is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the “Shares”) by Shockwave Medical, Inc.

via NewMediaWire – Neovasc Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the Company is executing for the Neovasc Reducer™ (“Reducer”) towards an approval decision for the device in the United States.

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina.

Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc.

Neovasc Inc. announced that the Centers for Medicare and Medicaid Services has assigned the Neovasc Reducer™ implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.